MKMichael R. Kujawa

Michael R. Kujawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael R. Kujawa has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Amy Lynn Hartman

    Center for Vaccine Research, University of Pittsburgh School of Medicine

    5 shared publications
  • Devin A. Boyles

    Affiliation Center for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

    3 shared publications
  • Douglas Scott Reed

    Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA 15261, USA

    2 shared publications
  • Joseph R. Albe

    Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA

    2 shared publications
  • Aaron W Walters

    Center for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

    1 shared publication
  • Aaron W. Walters

    Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA

    1 shared publication

Latest Publications

  • Top Cited Papers

    Lrp1 is a host entry factor for Rift Valley fever virus

    by Safder S. Ganaie, Madeline M. Schwarz, Cynthia M. McMillen, David A. Price, Annie X. Feng, Joseph R. Albe, Wenjie Wang, Shane Miersch, Anthony Orvedahl, Aidan R. Cole, et al.


  • Open Access

    Neutrophil and macrophage influx into the central nervous system are inflammatory components of lethal Rift Valley fever encephalitis in rats

    by Joseph R Albe, Devin A Boyles, Aaron W Walters, Michael R Kujawa, Cynthia M McMillen, Douglas S Reed, Amy L Hartman

    Rift Valley fever virus (RVFV) causes severe disease in livestock concurrent with zoonotic transmission to humans. A subset of people infected with RVFV develop encephalitis, and significant gaps remain in our knowledge of how RVFV causes pathology in the brain. We previously found that, in Lewis rats, subcutaneous inoculation with RVFV resulted in subclinical disease while inhalation of RVFV in a small particle aerosol caused fatal encephalitis. Here, we compared the disease course of RVFV in Lewis rats after each different route of inoculation in order to understand more about pathogenic mechanisms of fatal RVFV encephalitis. In aerosol-infected rats with lethal encephalitis, neutrophils and macrophages were the major cell types infiltrating the CNS, and this was concomitant with microglia activation and extensive cytokine inflammation. Despite this, prevention of neutrophil infiltration into the brain did not ameliorate disease. Unexpectedly, in subcutaneously-inoculated rats with subclinical disease, detectable viral RNA was found in the brain along with T-cell infiltration. This study sheds new light on the pathogenic mechanisms of RVFV encephalitis. Rift Valley fever is a disease of livestock and humans that occurs periodically in Africa and parts of the Middle East. People infected with Rift Valley fever virus can develop different clinical outcomes, including hemorrhagic fever or encephalitis. Understanding of the pathophysiological mechanisms of encephalitis has been a challenge due to inadequate animal models of neurological disease. We used a rat model of Rift Valley fever encephalitis to understand the mechanisms underlying lethal neurological disease compared to subclinical infection. The primary immune cell types that infiltrate the brains of rats with lethal encephalitis were neutrophils and macrophages. Prevention of neutrophil migration into the brains did not prevent disease. These results provide new insight into the contrast between lethal and subclinical disease in an immunocompetent rodent model of Rift Valley fever encephalitis.


  • Vascular permeability in the brain is a late pathogenic event during Rift Valley fever virus encephalitis in rats

    by Aaron W. Walters, Michael R. Kujawa, Joseph R. Albe, Douglas S. Reed, William B. Klimstra, Amy L. Hartman


  • Open Access

    Rift Valley fever virus induces fetal demise in Sprague-Dawley rats through direct placental infection

    by Cynthia M. McMillen, Nitin Arora, Devin A. Boyles, Joseph R. Albe, Michael R. Kujawa, Jeffrey F. Bonadio, Carolyn B. Coyne, Amy L. Hartman

    Rift Valley fever virus infection of pregnant rats results in fetal infection and death, even in dams with no signs of illness.


  • Open Access

    Inflammatory Biomarkers Associated with Lethal Rift Valley Fever Encephalitis in the Lewis Rat Model

    by Amy L. Caroline, Michael R. Kujawa, Tim D. Oury, Douglas S. Reed, Amy L. Hartman

    Rift Valley Fever (RVF) is an emerging viral disease that causes significant human and veterinary illness in Africa and the Arabian Peninsula. Encephalitis is one of the severe complications arising from RVF virus (RVFV) infection of people, and the pathogenesis of this form of RVF is completely unknown. We use a novel reproducible encephalitic disease model in rats to identify biomarkers of lethal infection. Lewis rats were infected with RVFV strain ZH501 by aerosol exposure, then sacrificed daily to determine the course of infection and evaluation of clinical, virological, and immunological parameters. Weight loss, fever, and clinical signs occurred during the last 1 – 2 days prior to death. Prior to onset of clinical indications of disease, rats displayed marked granulocytosis and thrombocytopenia. In addition, high levels of inflammatory chemokines (MCP-1, MCS-F, Gro/KC, RANTES, and IL-1β) were detected first in serum (3-5 dpi) followed by brain (5-7 dpi). The results of this study are consistent with clinical data from human RVF patients and validate Lewis rats as an appropriate small animal model for RVF encephalitis. The biomarkers we identified here will be useful in future studies evaluating the efficacy of novel vaccines and therapeutics.